Tufts D2d — Vitamin D + VDR Genotype Blocks Diabetes Progression 19%. Supplement Precision Medicine Era
SCIENCE

Tufts D2d — Vitamin D + VDR Genotype Blocks Diabetes Progression 19%. Supplement Precision Medicine Era

By Polly · · JAMA Network Open 2026 / Tufts D2d
KO | EN

The era of “just take vitamin D” ends. Tufts published D2d trial follow-up analysis in JAMA Network Open April 23, 2026 — 2,098 prediabetic adults genomic analysis + vitamin D 4,000 IU/day vs placebo. VDR (Vitamin D Receptor) gene AC/CC variant carriers (~70%): type 2 diabetes progression risk 19% reduction. AA variant (~30%): no vitamin D supplementation effect — high dose increases fall·fracture risk instead. First daily application of precision medicine (PGx·pharmacogenomics) for pre·post-menopausal women with increasing insulin resistance.

Historical Vitamin D Recommendation

Existing recommendation:

  • All adults: vitamin D 600~800 IU/day
  • Deficient: 2,000~5,000 IU/day
  • Blood 25(OH)D maintain 30~50 ng/mL

Expected effects:

  • Bone health·osteoporosis prevention
  • Immune function
  • Some data: cardiovascular·diabetes·depression·cancer adjunct

But the gap:

  • Different people respond differently to same dose
  • Effect ↓ in some large RCTs
  • High-dose side effects (hypercalcemia·kidney stone·falls)

Tufts D2d Trial Background

D2d (Vitamin D and Type 2 Diabetes):

  • US multicenter RCT
  • 2019 NEJM publication (primary result)
  • Prediabetic adults vitamin D 4,000 IU/day vs placebo
  • Primary result: vitamin D group showed 12% type 2 diabetes progression reduction (statistically borderline)

Primary result gap:

  • ↓ overall effect
  • Strong effect in some patients·no effect in others
  • “Why inconsistent?“

2026 Tufts Follow-up Analysis — VDR Genotype Analysis

Study design:

  • 2,098 D2d participants genomic analysis
  • VDR (Vitamin D Receptor) gene variants
  • Vitamin D 4,000 IU/day effect evaluation

Core variant: VDR rs2228570 (FokI):

  • AC/CC variants (~70% population)
  • AA variant (~30% population)

Key results:

VDR AC/CC variants (70%):

  • Vitamin D 4,000 IU/day → type 2 diabetes progression 19% reduction
  • Clear statistical significance
  • Vitamin D-responsive population

VDR AA variant (30%):

  • Vitamin D 4,000 IU/day → no effect
  • High dose ↑ fall·fracture risk
  • Vitamin D non-responsive population

Clinical significance:

  • Same dose effective in 70%·no effect (or harm) in 30%
  • Era of generic recommendation ends
  • VDR genotyping is supplement decision variable

Daily Application of Pharmacogenomics (PGx)

Existing PGx application areas:

  • Anticancer drugs (TPMT·DPYD testing)
  • Warfarin (CYP2C9·VKORC1)
  • Clopidogrel (CYP2C19)
  • Some psychiatric drugs (CYP2D6)
  • Limited to medical institutions·prescription drugs

Change Tufts D2d proposes:

  • Supplements (vitamin D) also PGx territory
  • PGx enters general daily territory
  • PGx influences home·pharmacy decisions, not just medical institutions

Future possibilities:

  • VDR + other vitamin genetic testing expansion
  • Omega-3·multivitamin·mineral PGx
  • Daily supplement decision precision medicine

Female Impact — Pre·Post-Menopausal Insulin Resistance

Pre·post-menopausal women shifts:

  • Estrogen decrease → ↑ insulin resistance
  • ↑ abdominal obesity (L69 UConn data)
  • ↑↑ type 2 diabetes risk
  • Gradual increase from late 30s

Vitamin D + insulin resistance:

  • Vitamin D deficiency + insulin resistance = ↑↑ diabetes risk
  • Postmenopausal women vitamin D deficiency common (UV avoidance + diet insufficient)

Tufts D2d meaning:

  • VDR AC/CC variant postmenopausal women: vitamin D 4,000 IU/day effective for diabetes prevention
  • VDR AA variant postmenopausal women: maintain standard dose (600~800 IU/day), avoid high dose
  • Precision decision via genotyping possible

VDR Genotyping

Testing methods:

  • Blood or saliva sample
  • Genetic testing labs (university hospitals·specialty clinics)
  • 23andMe etc DTC partial
  • Cost: Korea ₩100,000200,000

Korean introduction:

  • Some medical institutions
  • DTC: Macrogen·Theragen etc partial panels
  • No insurance coverage

When to test:

  • Family diabetes history
  • Prediabetic diagnosis
  • Vitamin D deficiency + high-dose supplementation decision
  • Pre·post-menopausal precision nutrition decision

Expansion of Supplement Label·Decision Matrix

L67·L68·L69 integration:

L67 Environmental hormone avoidance:

  • Sunscreen 4-MBC label check

L68 EPA·DHA separation:

  • Omega-3 EPA·DHA separate labeling
  • Decision by individual situation (repeated head impact)

L69 VDR + vitamin D:

  • VDR genotyping
  • 70% effective·30% no effect
  • Genotype-based decision

Common pattern:

  • No generic recommendation
  • Precision decision by label·testing·genotype·individual situation
  • Supplements like drugs in the decision era

Natural Matrix — Vitamin D Integrated Management

Natural sources:

  • UV (15~30 min/day, balanced with mineral sunscreen)
  • Salmon·mackerel·sardine (fish)
  • Egg yolks
  • Mushrooms (UV-exposed mushrooms ↑)
  • Fortified foods (milk·cereals etc)

Korean population vitamin D deficiency:

  • ~80% deficient (UV avoidance·indoor activity·diet)
  • Common testing·supplementation needed

Supplement decision:

  • Blood 25(OH)D measurement (medical institution)
  • Deficient (< 20 ng/mL): supplementation recommended
  • VDR genotyping (when available)
  • AC/CC variant: active supplementation possible
  • AA variant: maintain standard dose, avoid high dose

Diabetes Prevention Integrated Matrix

Diet:

  • Mediterranean·MIND
  • Fiber 25~35 g/day (L64 microbiome·L67 metabolome)
  • ↓ processed food·sugar
  • Protein 1.2~1.6 g/kg

Exercise:

  • 150+ min/week moderate (↓ insulin resistance)
  • Resistance exercise 2~3x/week

Drug matrix (if needed):

  • Metformin
  • L65·L66 GLP-1 (weight·insulin resistance)
  • Insulin (progressed)

Genetic testing:

  • VDR (L69)
  • APOE (L68)
  • PCSK9 variants
  • Family history-based panels

Korean Clinical Significance

Korean diabetes statistics:

  • 30+ age ~14% (2024)
  • Prediabetic ~25%+
  • Rapid postmenopausal female increase
  • Vitamin D deficiency very common

Korean medical options:

  • Vitamin D blood test: partial insurance (deficiency diagnosis)
  • VDR genetic test: self-pay (₩100,000~200,000)
  • Supplements: OTC, various doses
  • No insurance

Conclusion

Tufts D2d follow-up analysis is first daily PGx application case for supplements. End of generic “just take vitamin D” era. Precision decision via VDR genotyping. Especially meaningful for pre·post-menopausal women with increasing insulin resistance. L67 EDC label·L68 EPA·DHA·L69 VDR + vitamin D = supplement label·testing·genotype precision decision matrix. Supplements, like drugs, in the era of individual·genotype·situation-specific decisions. PGx dimension added to L68’s 30-pillar matrix.

Source: JAMA Network Open 2026 / Tufts D2d